Idiopathic Short Stature clinical trials at University of California Health
2 research studies open to eligible people
Showing trials for
Vosoritide in Children With Idiopathic Short Stature
open to eligible people ages 3-11
The purpose of this study is to evaluate i) the effect of multiple doses of vosoritide and ii) the effect of the therapeutic dose of vosoritide compared to human growth hormone (hGH)(hGH; only in the United States), in children with idiopathic short stature (ISS).
at UCSF
Growth in Children With Idiopathic Short Stature
open to eligible people ages 2-16
Study 111-903 will generate baseline growth data in children with ISS by collecting growth measurements and other variables of interest.
at UCLA UCSF
Last updated: